Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

CNTX - Context Therapeutics Inc. So'nggi... | Finranks

Home

CNTX

C

Context Therapeutics Inc. (CNTX)

NCM – Real vaqt narxi. Valyuta: USD

2.59

+0.05 (1.97%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.56

-0.03 (-1.16%)

Bozordan keyin: Mar 27, 2026, 4:47 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. “We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors.

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company's asset, CT-202, a Nectin-4 x CD3 TCE.

Context Therapeutics to Participate in Upcoming Investor Conferences

Context Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its participation in several upcoming investor conferences.

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025 in National Harbor, MD. CT-95 and CT-202 Highlights and Near-Term Milestones CT-95: Mesothelin x CD3 bispecific TCE CT-95 is avidity enhanced and affinity tuned to localize therapeutic activity to the tumor microenvironment.

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 million as of September 30, 2025 PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today provided a clinical update and reported its financial results for the third quarter ended September 30, 2025. “We believe the early clinical data for CTIM-76 provides encouraging early signs of antitumor activity for Context's T cell engagers (“TCE”) in solid tumors where many other approaches have failed due to material safety issues or lack of efficacy,” said Martin Lehr, CEO of Context.

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith, MD, PhD, MBA, LLM as its Chief Medical Officer (CMO) effective immediately.

Videolar

No Data

There is no data to display

Press-relizlar

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million as of December 31, 2025 expected to fund operations into mid-2027 PHILADELPHIA, March 23, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2025, and reported on recent and upcoming business highlights. “We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors.

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, CA. The presentation will highlight preclinical data regarding the Company's asset, CT-202, a Nectin-4 x CD3 TCE.

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced that Context has granted non-qualified stock option awards to purchase an aggregate of 120,000 shares of its common stock to two new employees as an inducement material for accepting employment with Context.

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today shared two posters discussing the Company's CT-95 and CT-202 programs at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting, being held November 7–9, 2025 in National Harbor, MD. CT-95 and CT-202 Highlights and Near-Term Milestones CT-95: Mesothelin x CD3 bispecific TCE CT-95 is avidity enhanced and affinity tuned to localize therapeutic activity to the tumor microenvironment.